



(V3-9-25-08)

Scientific Posters

Poster Session 1/2: AMD

Sunday, October 12, 9:45-10:15 am

101

Comparison of Visual Function Measured by Chart Acuity with that by the Field Acuity Analyzer in the Avastin® Treatment of CNVM with AMD

Yaprak Banu Unver MD

102

Vitamin and Alternative Medicine use in Patients with Advanced Age-related Macular Degeneration

Sunir J. Garg MD

103

Neovascular Age-Related Macular Degeneration in Patients with Cancer

Berdine M. Burger MD

104

Neovascular AMD Patients that still drive report more control and less dependence on others than non-drivers in ANCHOR

Ivan J. Suner MD

105

Correlation between Optical Coherence Tomography and Visual Acuity during Ranibizumab Treatment for Neovascular Age-related Macular Degeneration

Ying Han MD

106

Intravitreal Ranibizumab for the treatment of advanced macular dysfunction in patients with disciform fibrosis due to exudative ARMD

Nicole Lemanski BA

107

Functional and Anatomical Changes to Active Disciform Scars Secondary to Age-Related Macular Degeneration in Patients on Anti-VEGF Treatment

Dianne Marie-Boesch Schlachter MD

108

Early Lesion Morphology and Anatomic versus Functional Treatment Response to Ranibizumab Therapy for Exudative Age-Related Macular Degeneration

Hajir Dadgostar MD, PhD

109

Analysis of the Response of Multiple Intraocular Injections of Bevacizumab (Avastin®) in the Treatment of Neovascular Age-Related Macular Degeneration.

Hussein Wafapoor MD

110

1.25 mg vs 2.5 mg of Primary Intravitreal Avastin® in Neovascular ARMD: Results of the Pan American Collaborative Retina Study Group at 12 Months

Lihteh Wu MD

111

Retinal Angiomatous Proliferation (RAP) and Intravitreal Bevacizumab Injection

Ranjana Sanjay Mathur MD, FRCS (edin), MS

112

Treatment of Large Retinal Pigment Epithelium Detachment Associated with Age-Related Macular Degeneration with Bevacizumab or Ranibizumab

Paul J. Stewart MD

113

The Role of Anti-VEGF Agents in the Surgical Evacuation of Submacular Hemorrhage Associated with Age-Related Macular Degeneration

Arghavan Almony MD

114

Comparison of Treatment Options in the Treatment of Peripapillary Choroidal Neovascularization (CNV)

Matthew Sebastian Pezda MS, MD

115

A Comparative Study of Current Therapies for Neovascular Age-Related Macular Degeneration

William Michael Stapleton MD

116

The Triple Therapy in Choroidal Neovascularization Due to Age-Related Macular Degeneration

Mehmet Cakir MD

117

Verteporfin Combined with Ranibizumab in Polypoidal Choroidal Vasculopathy: Rationale and Design of the Phase IV SUMMIT EVEREST Study

Adrian H. C. Koh MBBS, FRCS(C)

118

Treating Wet AMD With Verteporfin PDT in Triple or Double Combination Therapy: Results of Two Visudyne® Registry Databases

Kent W. Small MD

Kent W. Small MD

119

SUMMIT: Study Design and Baseline Characteristics of the DENALI Trial Combining Verteporfin with Ranibizumab in Neovascular AMD

Jason S. Slakter MD



Scientific Posters

(V3-9-25-08)

- 120
PDT plus Avastin® in Naive and Non-naive Patients with Wet AMD
Jose A. Roca MD
- 121
Vitreotomy for Treatment of Breakthrough Vitreous Hemorrhage Secondary to Polypoidal Choroidal Vasculopathy in Asian Eyes—A Case Series
Boon-Kwang Loh MD, MBBS
- 122
Ocular Safety of Ranibizumab (LUCENTIS®) in Patients with Wet Age-Related Macular Degeneration: SAILOR and 3 Additional, Randomized, Multicenter Trials
Gregg T. Kokame MD, MMM
- 123
Systemic Safety and Risk Factors of Ranibizumab (LUCENTIS) in Patients with Neovascular Age-Related Macular Degeneration: Cohort 1 of SAILOR Study
Mark Michels MD
- 124
Persistent Ocular Hypertension Following Intravitreal Ranibizumab
Sophie J. Bakri MD
- 125
Bilateral Intravitreal Injections Of Bevacizumab Within One Week Are Not Associated With Increased Systemic Vascular Events
Ahmed Abdel-Azze El-Sanhouri MD
- 126
32 & 52 Week Results of a Phase 2, Randomized Controlled Dose; Interval-Ranging Study of Intravitreal VEGF Trap-Eye in Patients with Neovascular ARMD
David M. Brown MD
- 127
Safety and Efficacy of Epiretinal Brachytherapy & Bevacizumab for the Treatment Of Subfoveal CNV Secondary To AMD- VA & Safety at 18 Months
Jeffrey S. Heier MD
- 128
A Randomized, Prospective, Active Controlled, Study of Epiretinal Brachytherapy for the Treatment of Subfoveal Choroidal Neovascularization Associated with Wet Age-Related Macular Degeneration (CABERNET)
Michael A. Singer MD
- 129
Sirolimus (Rapamycin) Formulated For Local Delivery; Safety and Tolerability in Diabetic Macular Edema and Exudative Age-Related Macular Degeneration
Pravin U. Dugel MD

- 130
A Phase 2 Randomized, Double-Masked Study Comparing the Safety and Efficacy of Topical ATG003 1% and 3% Solutions to Placebo in Wet ARMD (OPTIMA Study)
Brian B. Berger MD
- 131
Evaluation Of Micro Collimated Pars Plana External Beam Radiation in the Eye
Rishi P. Singh MD
- 132
Targeted Photodynamic Therapy for the Treatment of Choroidal Neovascularization in a Rat Model
Ron A. Adelman MD, MPH
- 133
Pegaptanib (Macugen) Maintenance in Neovascular Age-Related Macular Degeneration (NV-AMD): Results of a Case Series
David S. Dyer MD
- 134
Intravitreal Anti-Fibroblast Agents in an Animal Model of Choroidal Neovascularization
Jeffrey L. Olson, MD

Poster Session 3: Diabetic Retinopathy Monday, October 13, 9:45-10:15am

- 301
Long Term Impact of Primary Care-Based Remote Assessment for Diabetic Retinopathy on the Rate of Documented Eye Evaluations in Patients with Diabetes.
Ingrid E. Zimmer-Galler MD
- 302
Diagnostic Value of Non-mydratiac Fundus Photography for Diabetic Retinopathy Screening in Remote Rural Sites versus an Urban Medical Center
Susanna S. Park MD, PhD
- 303
Initial Experience with Telemedical Diabetic Retinopathy Diagnosis in an Academic Medical Center
Reza Iranmanesh MD
- 304
Compliance with a Preferred Practice Pattern for Diabetic Retinopathy in a Resident Ophthalmology Clinic
Victoria L Tseng ScB
- 305
Intravitreal Bevacizumab in the Prevention of Early Postoperative Vitreous Hemorrhage in Diabetic Vitrectomy
Murat Oncel MD



Scientific Posters

306

Intravitreal Bevacizumab as an Adjunctive Treatment to PRP for High-risk PDR
Hyung Chan Kim MD

307

Intravitreal Bevacizumab in Combination with Triamcinolone Acetonide for the Treatment of Diffuse Diabetic Macular Edema
Osman Cekic MD, PhD

308

Intravitreal Bevacizumab (Avastin®)/Dexamethasone Combination for Diabetic Macular Edema
Jonathan M Gloth MD

309

Treatment of Refractory Diabetic Macular Edema: Triamcinolone vs Bevacizumab and "Switch-over" Treatment
Wai-Ching Lam MD

310

The Effect of Unilateral Intravitreal Bevacizumab (Avastin®), in the Treatment of Diffuse Bilateral Diabetic Macular Edema: A Pilot Study
Virgilio Morales-Canton MD

311

Intravitreal Dexamethasone as an Adjuvant Treatment for Refractory Diabetic Macular Edema
Yovanka M. Morilla MD

312

Ultra-widfield Angiography-directed Peripheral Laser and Anti-VEGF in Ischemia-driven Diabetic Macular Edema
Ivan J. Suner MD

313

Vascular Remodeling following Intravitreal Pegaptanib in Proliferative Diabetic Retinopathy
Victor Hugo Gonzalez MD

314

Pattern Scan Laser (PaScal) System vs Conventional Photocoagulation: Changes in Macular Thickness After Treatment
Jans Fromow-Guerra MD, PhD

315

Neuroprotective Strategies Timed with the PASCAL® (Pattern Scan Laser) Photocoagulation in the Treatment of Macular Edema in Patients with Diabetic Retinopathy
Michael D. Bennett MD

316

Pattern Scan Laser System (PaScal) vs Conventional Photocoagulation System: Electroretinogram Changes After Treatment
Virgilio Morales-Canton MD

(V3-9-25-08)

Poster Session 4: Retinal Vascular Disease/Retinal Detachment Monday, October 13, 9:45-10:15am

401

Clinical Management of CRVO in High Blood Pressure Mean Age Male Patients
Armando G. Sandoval MD

402

Retinal Vein Occlusion in Association with Traditional Risk Factors for Atherosclerosis
David T.W. Wong MD, FRCS(C)

403

Utilization of Optical Coherence Tomography to Examine the Acute Effects of Intravitreal Avastin® on Macular Edema Secondary to Non-Ischemic BRVO
Aaron J. Dent MD

404

Intravitreal Bevacizumab (Avastin®) Injection and Focal Macular Laser Treatment for Macular Edema due to Branch Retinal Vein Occlusion
Atsushi Hayashi MD

405

Resource Utilization and Direct Medical Costs for Elderly Patients with Incident Branch Retinal Vein Occlusion
Lesley H. Curtis PhD

406

Combination Intravitreal Triamcinalone and Bevacizumab Injection is an Effective Treatment for Macular Edema Secondary to Retinal Vein Occlusions
Alan J. Franklin MD, PhD

407

Combination Therapy for Branch Retinal Vein Occlusion
Martin A. Boscarino MD

408

Development of collateral vessels under Avastin®-Therapy for branch retinal vein occlusion
Jörg C. Schmidt MD, PD

409

Peripheral Non-Perfusion and Late Peripheral Vessel Leakage – The Angiographic Index for Central Retinal Vein Occlusion?
Scott C. Oliver

410

Laser Photocoagulation Following Intravitreal Bevacizumab for Central Vein Occlusion
David Hauser MD



Scientific Posters

411

Evaluation of Aqueous VEGF Levels after Intravitreal Bevacizumab for Retinal Vein Occlusions

Shailesh K. Gupta MD

412

Efficacy and Safety of Ocular Photodynamic Therapy with Verteporfin for Chronic Central Serous Chorioretinopathy

Sadun Yalcin MD

413

Short-term Complications of 20mg Intravitreal Triamcinolone Injections

Jonathan M Gloth MD

414

The Morphology of Phakic and Pseudophakic Retinal Detachments

Peter J. Kertes MD, FRCS(C)

415

Why the Retina Re-attaches after Scleral Buckling Surgery:

A Fluid and Structural Mechanical Approach

William J. Foster MD, PhD, FRCS(C)

416

Short Term Intraocular Tamponade with Perfluorocarbon Heavy Liquids

Matt Russell MD

417

Proliferative Vitreoretinopathy in Siderosis Bulbi

Aneesh Neekhra MD

418

Endothelial Membrane Protein-2 (EMP-2) as a Potential Therapeutic Target for Proliferative Vitreoretinopathy (PVR) and its role in RPE Migration

David Gregory Telander MD

419

Central Serous Chorioretinopathy Associated with Ephedra Usage

Kristine K. Pierce MD

(V3-9-25-08)

Poster Session 5: Surgical Techniques and Maneuvers/Pharmacology

Tuesday, October 14, 7:00-7:30am

501

High Frequency Arc-Scan Anterior Segment Ultrasonographic Study of 23-Gauge Vitrectomy Sclerotomies

Sophia I. Pachydaki MD

502

Dynamic Evaluation of Sutureless Vitrectomy Wounds: An Optical Coherence Tomography and Histopathology Study

Mehran Taban MD

503

Comparison of Non-Sutured 20 gauge MVR and 20 gauge Trocar/ Cannula Sclerotomy Wounds

Philip J. Ferrone MD

504

To Stitch or not to Stitch Small-gauge Sclerotomies when using Silicone Oil?

Joao Luiz Lobo Ferreira MD

505

Full Macular Translocation using 23 Gauge System without Scissors: "Cau-Tano" Technique

Cesare Forlini MD

506

Secondary IOL Implantation in Mini-Invasive Transconjunctival Era

Cesare Forlini MD

507

Long-term Results of Sling Technique Scleral Sutured Posterior Chamber Intraocular Lens (PCIOL) in Complicated Dysphakic Eyes

Janice Chung-See Law MD

508

Combined Phacoemulsification, Posterior Chamber Lens Implantation, Pars Plana Vitrectomy, Pars Plana Tube, and Retisert in Non-infectious Panuveitis

Christopher N. Singh MD

509

En Bloc Perfluorodissection for Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

J. Fernando Arevalo MD, FACS

510

Incidence of Cystoid Macular Edema Related to Surgery for Retained Lens Fragments Combined with Peeling of the Internal Limiting Membrane

Gaurav K. Shah MD



Scientific Posters

511

Conjunctival Contamination of Vitreous in Pars Plana Vitrectomy
Mark Kropinak MD

512

Is an Eyelid Speculum Necessary for Intravitreal Injections?
Michael W. Stewart MD

513

Comparison Between 20 Gauge Transconjunctival Sutureless
Vitrectomy (TSV) and 23 Gauge TSV for Rhegmatogenous Retinal
Detachment (RRD)
Francesco Boscia MD

514

Single Intraocular Injection Formulation for Bevacizumab and
Triamcinolone Acetonide
John E. Thordsen MD

515

Evaluation of in Vitro Toxicity of Bevacizumab (Avastin®) on
Choroidal Endothelial and Retinal Ganglion and Cells
K.V. Chalam MD, PhD, MBA, FRCS(C)

516

Posterior Vitreous Detachment Alters Retinal Penetration of
Intravitreal Bevacizumab (Avastin®) In Rabbit Eyes
David Todd Goldenberg MD

517

The Long Term Stability of Reconstituted Infliximab (Remicade)
Solution for Intravitreal Injection
Paul Marius Beer MD

518

Anecortave Acetate in Eyes with Steroid-Induced Ocular
Hypertension Inadequately Controlled With Topical Intraocular
Pressure-Lowering Medications
Karim Nasiruddin Jamal MD

519

Does Speed of Injection Affect the Incidence of Nausea in Patients
Undergoing Fluorescein Fundus Angiography?
Paul Elimia Tesha MD

(V3-9-25-08)

Poster Session 6: Imaging - Digital - Angiography/Ocular Oncology/ Inflammatory and Infectious Diseases Tuesday, October 14, 7:00-7:30am

601

Spectral Domain Optical Coherence Tomography Imaging of
Retinal Diseases in Singapore
Mandeep Singh MBBS MRCSEd Mmed (Ophth)

602

Normative Data for Macular Thickness by Spectral-domain OCT
(Spectralis)
Sandeep Grover MD

603

Time-domain OCT (Stratus) underestimates Macular Thickness in
Normal Subjects as Compared to Spectral-domain OCT
(Spectralis)
Sandeep Grover MD

604

Comparison of Four different Spectral Domain Optical
Coherence Tomography (OCT) Devices with the Stratus Time
Domain OCT Device
Peter K. Kaiser MD

605

Intravitreal anti-VEGF Treatment and Associated Retinal Nerve
Fiber Layer Thickness Changes as Assessed by Optical Coherence
Tomography
Drew N. Sommerville MD

606

The Use of Ultra-Widefield Photography and Fluorescein
Angiography in the Management of Retinal Disease
Thomas W. Stone MD

607

Digital Interference Holography Imaging of Human Macula
Christine Nichols Kay MD

608

Clinical Differentiation of Coats' Disease from Retinoblastoma
Jerry A. Shields MD

609

Malignant Pseudohypopyon: An Unusual Case of Metastatic
Squamous Cell Lung Carcinoma to the Choroid
Blaine E. Cribbs MD

610

25-Gauge Transconjunctival Sutureless Vitrectomy for the
Diagnosis of Intraocular T- and B-cell Lymphoma
Steven Yeh



(V3-9-25-08)

Scientific Posters

- 611
Ocular Safety of Intravitreal Immunotoxin HA22, a Recombinant Protein Targeting B-cell Lymphoma, in a Rabbit Model
Lisa J. Faia MD
- 612
Plaque Location Affects The Incidence of Cataract and Retinopathy after Ophthalmic Radiation Therapy: An Analysis of 384 Consecutive Cases
Neil S. Patel MD, MS
- 613
Preliminary Results of Ranibizumab Adjuvant Therapy for the Treatment of Choroidal Melanoma
David Tom MD
- 614
Kenalog-40 Induces Cytokine Secretion and Cellular Abnormalities In U-937 Human Macrophages: A Model of Sterile Endophthalmitis?
Jeffrey Edelman
- 615
Dexamethasone in an Intravitreal Drug Delivery System Decreases Levels of Inflammatory Mediators in a Model of Experimental Uveitis
James Burke BSc
- 616
Design of the Phase 3 Clinical Trials of a Novel Calcineurin Inhibitor, LX211, for the Treatment of Non-infectious Uveitis
Quan Dong Nguyen MD, MSc
- 617
Retisert Implant for Birdshot Chorioretinopathy
Naomi S. Falk MD
- 618
Intravitreal Larval Trematode with a Novel Route of Infection
Thomas W. Hejkal MD, PhD
- 619
Toxic Anterior Segment Syndrome (TASS) Presenting as Infectious Endophthalmitis
Hussein Wafapoor MD

Poster Session 7: Trauma/ Pediatric Retina - ROP/ Complications of Anterior Segment Surgery Tuesday, October 14, 9:45 -10:15am

- 701
"Pole to Pole" Surgery as Gold Standard in Severe Trauma Cases
Matteo Forlini MD
- 702
Traumatic Brain Injury Associated with Combat Ocular Trauma
Eric D. Weichel MD
- 703
Pars Plana Vitrectomy in the Management of Exogenous Endophthalmitis in Pediatric Age Group
Osman Cekic MD, PhD
- 704
Early Vitrectomy Effective for Norrie Disease
Mark Walsh MD
- 705
Intravitreal Bevacizumab for Idiopathic Choroidal Neovascularization in a Child
Mehmet Cakir MD
- 706
A Case Series of Intravitreal Anti-VEGF use for the treatment of Choroidal Neovascular Membranes in the Pediatric Population
Wai-Ching Lam MD, FRCS(C)
- 707
Vascular Endothelial Growth Factor Levels in Aqueous, Vitreous, Blood and Subretinal Fluid in Patients with Stage V Retinopathy of Prematurity
Hugo Quiroz-Mercado MD
- 708
Electroretinogram Findings after Intravitreal Bevacizumab for Retinopathy of Prematurity
Jose Luis Guerrero-Naranjo MD
- 709
Combination Therapy as an Alternative and Effective Treatment Modality for Chronic Pseudophakic CME
Keith A. Warren MD



Scientific Posters

Poster Session 8: Macular Pucker, ERM, Macular Holes

Tuesday, October 14, 9:45 -10:15am

801

Atypical Outcomes in Macular Vitreoretinal Interface Surgery: A Case Series
Paul B. Griggs MD

802

Long-term Outcomes after Surgery for Idiopathic Epiretinal Membranes as determined by serial optical coherence tomography
Jane Suechung Myung

803

Vitrectomy with Membrane Peeling for Epiretinal Membranes in eyes with Neovascular Age-related Macular Degeneration
Saad Ahmad MD

804

The Configuration of Idiopathic Macular Hole: its Correlated Preoperative Factors and Predictability for Anatomical Outcome
Wu Liu MD

805

Bilateral Sequential Same Day 25-Gauge Macular Hole Surgery
Benjamin W. Roberts MD

806

ILM as an Adjuvant for Stage IV Macular Hole Surgery
Zofia Michalewska MD

807

Electron Microscopic Appearance of Internal Limiting Membrane Specimens Obtained during Macular Hole Surgery
Bryan J. Schwent MD

808

Re-operation of Idiopathic Full Thickness Macular Holes after Initial Surgery with Internal Limiting Membrane Peel
Varun Chaudhary MD

(V3-9-25-08)

Poster Session 9: Instrumentation and Devices/Socioeconomics/Hereditary Retinal Disease and Genetics

Tuesday, October 14, 9:45 -10:15am

901

Evaluation of Ultra Wide-angle 'Ora-Ora' High Refractive Index Self-stabilizing Wide-angle Contact Lens for Vitreous Surgery
K.V. Chalam MD, PhD, MBA, FRCS(C)

902

Comparison between the Foresee Home Perimeter and the Amsler Grid, in Patients with Age Related Macular Degeneration
Anat Loewenstein MD

903

Transconjunctival Delivery Of Ranibizumab And Triamcinolone Acetonide To Retinal Tissues Using Nanodielectrophoresis
Rishi P. Singh MD

904

Conjunctival Pigmentation - an Unusual Complication of 23-gauge Sutureless Pars Planar Vitrectomy
Edmund Y.M. Wong MBBS, FRCSEd, Mmed

905

Development of a self-administered visual function questionnaire (VFQ) for a hand held Palm Pilot PDA
Stephen H. Sinclair MD

906

New Advancements in Vitreous Cutters
Peter K. Kaiser MD

907

Criteria for Ranking Retina and Vitreous Fellowship Candidates
Ron A. Adelman MD, MPH

908

Project VISION: Free Mobile Eye Screening Unit Brings Early Disease Detection to the Communities of Hawai'i
Philip H. Scharper MD

909

Macular Function in Patients with Enhanced S Cone Syndrome due to Mutation in NR2E3
Elliott H. Sohn MD